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Glomerular hypertension and injury persist in clesoxycorticoster-
one—salt rats on antihypertensive therapy. Uninephrectomized male
Munich—Wistar rats received either weekly subcutaneous injections of
vehicle and water for drinking; injections of desoxycorticosterone
(DOC) and 1% saline (SALT) for drinking; or DOC and SALT with
hydrochlorthiazide, hydralazine, reserpine and KCI added. All studies
were performed six weeks after UNX. At that time, rats receiving DOC
and SALT alone were hypertensive and had significantly more protein-
uria and morphologic evidence of glomerular injury than rats given
vehicle and tap water which were normotensive. Antihypertensive
therapy normalized mean arterial pressure in DOC-SALT rats, but
failed to prevent proteinuria, mesangial expansion or focal segmental
glomerular lesions. Micropuncture studies revealed that glomerular
capillary pressure was elevated in both untreated and treated DOC-
SALT animals. We conclude that drugs which successfully reduce
systemic blood pressure may fail to correct glomerular capillary hyper-
tension in DOC-SALT rats. As persistence of intrarenal hypertension is
associated with significant glomerular injury, normalization of glomer-
ular capillary pressure rather than systemic arterial pressure is crucial
to the prevention of glomerular injury in this model.
Recent studies in the Holtzman rat [1], spontaneously hyper-
tensive rat (SHR) [2], remnant kidney [3], and desoxycortico-
sterone—salt (DOC-SALT) [4] models of hypertension suggest
that glomerular injury in hypertension is hemodynamically
mediated and results from increased hydraulic pressure within
the glomerular capillary. If so, then pharmacologic reduction of
systemic blood pressure might be expected to cause glomerular
capillary pressure to decline and thereby protect the kidney
from injury. However, studies in both patients and experimen-
tal animals suggest that the renal circulatory effects of the
various antihypertensive agents may differ significantly. For
example, whole kidney clearance studies indicate that /3 adren-
ergic blockers, such as propranolol, may decrease renal plasma
flow (RPF) when administered to hypertensive patients [5]
whereas hydralazine, a vasodilator, may increase RPF [61. This
latter observation is significant, as Feld et al [7] have reported
that adequate control of AP achieved by administration of
hydrochlorthiazide, reserpine and hydralazine failed to prevent
glomerular sclerosis in SHR. Similarly, Purkerson, Hoffsten
and Klahr [8] reported that this same antihypertensive regimen
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did not completely protect rats subjected to extensive reduction
in renal mass from glomerular injury.
One possible explanation for this apparent paradox is that
administration of a substance which dilates both systemic and
renal blood vessels might reduce mean arterial pressure (AP)
but not glomerular capillary hydraulic pressure (PGC) and
therefore not lessen glomerular damage. To further examine the
pathogenesis of the glomerular damage that occurs in experi-
mental hypertension and the impact of antihypertensive therapy
on that injury, we correlated the structural and hemodynamic
changes that occur in the glomeruli of rats with DOC-SALT
hypertension that were untreated or treated with hydrochlor-
thiazide, reserpine and hydralazine.
Methods
Studies were performed in six groups of uninephrectomized
(UNX) male Munich—Wistar rats (Simonson Laboratories, Cal-
ifornia, USA) with initial weights of 175 to 200 g. Rats in groups
I (N = 6) and 4 (N = 10) received weekly subcutaneous
injections of peanut oil and water for drinking. Groups 2 (N =
6) and 5 (N = 9) received weekly injections of 10 mg of
desoxycorticosterone acetate (DOC) in peanut oil and were
given 1% saline for drinking. Group 3 (N = 6) and group 6 rats
(N = 10) also received weekly injections of DOC but were given
a solution for drinking which contained 1% saline, KCI 20
mEq/liter, hydrochlorthiazide 200 mg/liter, hydralazine 100
mg/liter and reserpine 2 mg/liter. Throughout the study, rats
ingested standard chow containing 24% protein by weight
(Teklad). All studies were performed 6 weeks after UNX.
Urinary protein studies
On the day prior to sacrifice, animals in groups 1 to 3 were
placed in metabolic cages and 24-hour urine collections were
made for determination of protein excretion rate. Urinary
protein concentration was measured by precipitation with 3%
sulfosalicylic acid. Turbidity was then determined by measuring
absorbance at a wavelength of 595 m using a Coleman Junior
II spectrophotometer.
Morphologic studies
On the day of sacrifice, rats in groups Ito 3 were anesthetized
with mactin (100 mg/kg body wt, i.p.). The left femoral artery
was cannulated and mean arterial pressure directly measured
using a Statham pressure transducer (Statham Instruments,
Oxnard, California, USA) connected to a Grass recorder. The
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hemorrhage, necrosis and aneurysmal dilatation in varying
combinations. A focal segmental glomerular lesion is depicted
in Figure 3.
Cortical micropuncture studies
Grade of mesangial expansion
Fig. 1. Incidence and severity of mesangia! expansion in DOC-SALT
rats. Bars indicate the percent (Mean SE) of glomeruli with grade 0 to
3 mesangial expansion in control (group 1, U) and treated (group 3, )
oruntreated (group 2, ) DOC-SALT rats. ap < 0.05 vs. group I; bp <
0.05 vs. group 3.
kidney was exposed via a left subcostal incision andthen fixed
in situ by perfusion for five minutes at the measured arterial
pressure with 1.25% glutaraldehyde in 0.1 M cacodylate buffer
(pH 7.4). After fixation, two coronal slices of each kidney,
which included one pole and the middle portion, were proc-
essed routinely for light microscopy through paraffin embed-
ding. Four micron thick large sections with 182 to 287 glomeruli
per section were examined for evaluation and quantitation of
focal glomerular lesions. Two micron thick and, of necessity,
smaller sections with 82 to 122 glomeruli per section were used
for evaluation and quantitation of mesangial abnormalities.
Sections were stained with hematoxylin/eosin (H & E).
Slides were coded and examined in a blinded fashion by one
observer (H.F.). The mesangial region of each glomerulus was
assessed and graded as "0" if of normal area, "I" if mildly
increased in area, "2" if moderately increased in area, or "3"
if markedly increased in area (Fig. I). All glomeruli were
counted and the number of glomeruli with each degree of
mesangial expansion was expressed as a percentage of the total
number of glomeruli in the sample. A composite mesangial
expansion score was then calculated for each rat according to
the formula:
Mesangial expansion score = 0 x (% grade 0 glomeruli) + I
x (% grade I glomeruli) + 2 x (% grade 2 glomeruli) + 3 X
(% grade 3 glomeruli)
In all groups, an increase in mesangial area was due to an
increase in cells and/or matrix. Examples of glomeruli with
mesangial grades 0 to 3 are presented in Figure 2. Focal
glomerular lesions were counted and expressed as a percentage
of the total number of glomeruli in the section. Focal lesions
displayed a spectrum of features; all were acute and most were
segmental but some were global. The changes included endo-
capillary proliferation and leucocytic infiltration, crescents,
Six weeks after UNX, rats in groups 4 to 6 were anesthetized
with mactin (100 mg/kg body weight, i.p.) and prepared surgi-
cally for micropuncture study. Briefly, immediately after induc-
tion of anesthesia, a polyethelene catheter was inserted into the
left femoral artery and 100 d of blood collected for determina-
tion of hematocrit, plasma sodium and plasma potassium con-
centration. A tracheostomy was performed and polyethelene
catheters inserted into the jugular veins and ureter for infusion
of solutions and collection of samples. The kidney was exposed
via a left subcostal incision, placed on a lucite holder and
bathed in normal saline heated to 37°C. To compensate for the
loss of plasma associated with anesthesia and surgery, all rats
received intravenous infusions of a volume of heparinized
isoncotic rat plasma equal to 10 ml per kg body weight over 20
to 30 minutes, followed by sustaining infusions of plasma at
approximately 0.5 ml per hour, adjusted to maintain hematocrit
stable at baseline values. In addition, all rats received a 0.5 ml
intravenous bolus of [3H]-methoxyinulin (New England Nu-
clear, Boston, Massachusetts, USA) (120 pCi/ml) in normal
saline followed by a sustaining infusion of inulin at a rate of 0.5
ml per hour.
After a 45 minute equilibration period, exactly timed collec-
tions of proximal tubule fluid were obtained by micropuncture
for determination of inulin content by liquid scintillation count-
ing. Plasma and urine inulin concentrations were similarly
determined and these measurements used to calculate SNGFR
and whole kidney GFR by standard formulae [9]. Femoral
arterial and efferent arteriolar blood samples were obtained for
measurement of total protein concentration by the method of
Viets et al [10]. Hydraulic pressure in glomerular capillaries,
cortical tubules and efferent arterioles was directly measured
using the servo-null micropipette technique [9]. Calculation of
the determinants of glomerular ultrafiltration and vascular re-
sistances were made using standard formulae as set out by
Baylis et al [9]. Plasma sodium and potassium concentration
were determined by standard flame photometry.
Analysis of data
Statistical analysis was performed by Kruskal—Wallis Test
(Chi—Square Approximation) [11] or by one—way analysis of
variance followed by computation of modified t-values and
multiple pair—wise comparisons according to the method of
Bonferroni [12]. Statistical significance was defined asP < 0.05.
Results
Whole animal data
Mean values for body weight, AP, 24-hour protein excretion
and perfused kidney weight at the time of sacrifice for rats in
groups I through 3 are given in Table 1. All rats gained weight
over the six week period from time of UNX to sacrifice. Mean
arterial pressure was significantly increased in group 2 rats by
almost 40 mmHg compared with rats in group I. Administration
of hydrochlorthiazide, hydralazine and reserpine (HHR) re-
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Fig. 2. Glomeruli illustrating mesangial expansion by increased cells and matrix of grades 0 - 3 respectively. (H&E, x550)












1 277 118 15.0 2.485
2 265 l57 56.7' 2.853
3 294" 93'" 69.8 2.686
Mean SE
P < 0.05 vs. I
b P < 0.05 vs. 2
cant proteinuria, excreting at least as much protein in 24 hours
as did untreated DOC-SALT rats in group 2. Perfused kidney
weight was not different among these three groups.
Fig. 3. Segmental lesion characterized by cellular proliferation,
leucocytic infiltration and capsular adhesion. The rest of the tuft Morphologic studies
illustrates grade I mesangial expansion (H&E, x550). Mean values for the percentage of glomeruli showing grade 0
to 3 mesangial expansion for rats in groups I to 3 are displayed
SALT rats in group 3, to a value which was significantly less in Figure 1. Mesangial widening was present in all three groups,
than that observed in both groups I and 2. However, despite a consequence of the fact that all rats underwent UNX six
prevention of systemic hypertension, group 3 rats had signifi- weeks prior to sacrifice. Nevertheless, group I rats had signif-
.S •
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Table 2. Summary of morphologIc data
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P < 0.01 vs. I
icantly more normal (grade 0) glomeruli (23 3%) than either
groups 2 (7 2%) or 3 (12 3%). Conversely, grade 3 lesions
were uncommon in group I rats, involving less than 4% of
glomeruli. These severe lesions occurred in 32%ofglomeruli of
group 2 rats and 13% of glomeruli of group 3 rats. A normal
glomerulus and glomeruli showing grade I to 3 mesangial
expansion are shown in Figure 2.
The mesangial expansion score (MES) is a number which
integrates the incidence and severity of mesangial involvement
in individual rats. Mean values for MES and the mean percent-
age of glomeruli displaying focal segmental lesions for rats in
groups I to 3 are presented in Table 2. Untreated DOC-SALT
rats in group 2 had a significantly higher MES than control rats
in group I. Rats in group 3 had a mean value for MES which
was intermediate between groups I and 3. Focal glomerular
lesions (Fig. 3) were identified in three of six group 2 untreated
DOC-SALT rats, affecting 1.2%, 3.75%and 0.55% ofglomeruli,
respectively. Such lesions were identified in five of six group 3
treated DOC-SALT rats, affecting 2.08%, 0.88%, 0.92%, 3.08%
and 1.14% of glomeruli, respectively. Thus, as summarized in
Table 2, the mean incidence of focal segmental lesions was not
reduced by antihypertensive therapy in group 3 as compared
with group 2 rats. Focal segmental lesions were not observed in
group I animals. Thus normalization of systemic blood pressure
with HHR failed to prevent significant disruption of normal
glomerular architecture in DOC-SALT rats (group 3).
Micropuncture studies
Mean values for body weight, Hct, A, plasma [Na] and [K],
and the pressures, flows and resistances governing glomerular
ultrafiltration for rats in groups 4 to 6 are displayed in Table 3.
Body weight and Hct were similar at the time of micropuncture
study in all three groups. AP was elevated only in group 5 rats,
by 55 mm Hg as compared with group 4. Once again, adminis-
tration of HHR reduced AP in DOC-SALT rats, to a value in
group 6 which was numerically but not significantly lower than
that seen in group 4. In addition to systemic hypertension,
DOC-SALT rats_in group 5 displayed glomerular capillary
hypertension, as pOC was increased by 10 mm Hg as compared
with group 4. Since T was similar in these 2 groups, P was
also significantly elevated in group 5 rats, by 28% as compared
with group 4. Importantly, despite normalization of AP, admin-
istration of HHR failed to significantly reduce either PGC or P
of DOC-SALT rats in group 6. The calculated values for
afferent and efferent arteriolar resistance revealed the mecha-
nism by which PGC remained elevated in group 6 rats. In
response to an increase in perfusion pressure, RA increased by
66% in group 5 as compared with group 4 rats. However, this
increase was not sufficient to prevent DOC-SALT rats from
developing significant glomerular capillary hypertension. With
administration of HHR, AP and RA fell in group 6, the latter to
a value which was numerically but not significantly less than
that observed in group 4. This reduction in RA combined with a
small, not statistically significant increase in RE in group 6 as
compared to group 4 rats resulted in an 8 mm Hg increase in POC
in group 6 versus group 4.
GFR, SNGFR, QA, and SNFF were similar in all three
groups, despite the fact that P was increased in groups 5 and
6 as compared with group 4. As values for CA were not different
in groups 4 to 6, the only other possible explanation for the
similar values for SNGFR observed in these three groups is that
K1 must have declined in groups 5 and 6. Indeed, calculated
values for Kf were reduced in groups 5 and 6, by 51% and 60%
respectively as compared with group 4. Finally, serum values
for [Na] and [K] were similar in all three groups.
Discussion
In 1968, Hill and Heptinstall [13] reported that one of the
earliest and most dramatic alterations of renal architecture
observed in DOC-SALT rats was marked dilation of the efferent
glomerular vasculature. They suggested that this alteration
resulted from a functional abnormality of the afferent arteriole,
a failure to autoregulate, which rendered the glomerulus and
efferent arteriole vulnerable to dilation and hyperdistention by
rising blood pressure. Ultimately, this hydraulic stress was
responsible for the appearance of vascular and glomerular
injury. Recent direct measurements of glomerular pressures,
flows and resistances in Munich—Wistar rats with DOC-SALT
hypertension [4] support this hypothesis. As predicted, afferent
arteriolar resistance was found to be reduced and glomerular
capillary hydraulic pressure and plasma flow elevated in DOC-
SALT rats early in the course of hypertensive nephrosclerosis.
Furthermore, protein restriction, which reduced glomerular
capillary pressure and flow, protected DOC-SALT rats from
glomerular injury. In close agreement with this previous report,
PGC and zP were found to be elevated in DOC-SALT rats in the
present study, as compared with UNX controls, suggesting that
increased glomerular capillary pressure is itself responsible for
glomerular injury in this model of hypertension. In fact, studies
in Holtzman rats with "post-salt" hypertension [I], in rats with
2-kidney, I-clip Goldblatt hypertension [14—16], in the remnant
kidney [3], and in uninephrectomized, spontaneously hyperten-
sive rats (SHR) [2] strongly support the hypothesis that eleva-
tion in glomerular capillary pressure is a common mechanism of
glomerular injury in hypertension.
Applying the preceding hypothesis to therapeutics, if one is
to prevent renal injury in hypertension, then one must devise
therapy which reduces hydraulic pressure within the glomerular
capillary. In several of the studies described above, a low
protein diet was effective in lowering glomerular capillary
pressure, flow and filtration rate and preventing glomerular
injury. Unfortunately, as reviewed elsewhere [17], protein
restriction may not be suitable for widespread application to the
treatment of renal disease in humans. For renal diseases asso-
ciated with hypertension, a logical alternative would seem to be
the numerous antihypertensive agents which are currently
722 Dworkin ci a!
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C Only a minimum value for K1 determined in two rats
utilized to reduce systemic blood pressure. However, as noted
previously, studies in both the SHR [7] and the remnant kidney
model [8] of hypertension suggest that standard antihyperten-
sive therapy may sometimes fail to prevent hypertensive neph-
rosclerosis. In fact, based upon this apparent paradox, the
authors of both of these studies concluded that hemodynamic
factors were not central to the development of renal disease in
these models.
Our findings on the failure of antihypertensive therapy pre-
vent renal injury in experimental hypertension are in close
agreement with these previous reports. Thus, both morphologic
and proteinuric evidence of glomerular injury persisted in
DOC-SALT rats despite prevention of systemic hypertension
achieved by administration of hydrochlorthiazide, hydralazine
and reserpine. However, our micropuncture data provide a
simple, alternative explanation for this apparent paradox. In
preceding studies, it was assumed that reductions in systemic
arterial pressure were associated with similar declines in hy-
draulic pressure within the kidney. In fact, direct measurements
revealed that glomerular capillary pressure remained elevated
despite normalization of systemic pressure in DOC-SALT rats
treated with HHR. Furthermore, persistence of glomerular
capillary hypertension was associated with the development of
significant proteinuria and morphologic evidence of glomerular
injury in group 6 rats. Thus, hemodynamically—mediated
glomerular injury may occur despite prevention of systemic
hypertension in DOC-SALT rats. By analogy, it is likely that
persistence of glomerular capillary hypertension may also ac-
count for the failure of HHR to prevent glomerular injury in the
remnant kidney and SHR models of hypertension. In fact,
Anderson, Rennke and Brenner [18] have recently reported that
glomerular capillary hypertension is not prevented in rats with
reduced renal mass by treatment with HHR.
Despite the close association between glomerular capillary
hypertension and the development of glomerular sclerosis and
proteinuria in our rats, several observations suggest that factors
other than intrarenal hypertension contribute to glomerular
injury in experimental hypertension. For example, although
glomerular capillary pressure is similarly elevated in UNX SHR
and DOC-SALT hypertensive rats [2, 4], glomerular injury
takes several months to appear in SHR yet develops in weeks in
DOC-SALT rats. Therefore, nonhemodynamic factors may
account for the more rapid pace of glomerular injury in mm-
eralocorticoid hypertension. Furthermore, as previously dis-
cussed, antihypertensive therapy was not totally without ben-
eficial effect in the intact SHR [71 and remnant models [8], but
did delay or diminish glomerular injury even though glomerular
hypertension was probably not prevented. Finally, in the pres-
ent study, persistance of glomerular hypertension in group 3
rats was associated with no reduction in proteinuria or focal
segmental lesions, yet mesangial expansion was less in this
group as compared with group 2. The explanation for this
finding is uncertain, however, it suggests that focal lesions did
not evolve from mesangial expansion in these rats and that
these two types of glomerular abnormalities may be have
derived from different pathogenic processes. On balance, how-
ever, the data support the hypothesis that elevation in glomer-
ular capillary pressure is an important mechanism of glomerular
injury and that reduction of systemic pressure without concom-
itant reduction of glomerular pressure does not protect the
kidneys of these animals from significant structural damage.
Why reduction in systemic blood pressure with HHR should
fail to reduce glomerular capillary pressure is uncertain. In both
the DOC-SALT rat reported here and in the remnant kidney
model described by Anderson, Rennke and Brenner [18], PGC
failed to decline because antihypertensive therapy caused se-
lective reduction in afferent arteriolar resistance to extremely
low values, while efferent resistance was unchanged or even
increased. One possibility is that drug therapy caused direct
relaxation of afferent arteriolar smooth muscle, thereby reduc-
ing RA. Although it is impossible to determine from the present
study which of the administered agents might have been respon-
sible for this vasodilation, of the three, only hydralazine has
been consistently reported to decrease renal vascular resistance
and to increase renal blood flow in hypertensive patients [6].
However, to date, the action of this drug as a single agent on the
renal microcirculation has not been specifically examined.
It is likely that other antihypertensive agents are more
effective than HHR in preventing hemodynamically—mediated
renal injury. For example, the angiotensin converting enzyme
inhibitor, enalapril, has been reported to reduce PGC in rats
after reduction in renal mass [19] or with experimental diabetes
[201. In both settings, glomerular injury was also ameliorated.
Experimental diabetes is a particularly important model be-
cause systemic hypertension [211 is not a feature of untreated
diabetic rats. Nevertheless, glomerular capillary pressure and
flow are increased and probably contribute to glomerular injury
in these animals. Accordingly, therapy with antihypertensive
agents may be useful in delaying progression of renal diseases
like diabetic nephropathy, which are sometimes characterized
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0.89 0.36 2.33 85.2 240 0.119c 0.92 0.83 1.75 153 3.3
±0.03 ±0.01 ±0.19 ±5.5 ±21 ±0.013 ±0.07 ±0.06 ±0.13 ±1 ±0.1
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O.6l 0.32 2.28 77.3 245 0.048 074b 1.10 184b 146 3.3
±0.03 ±0.01 ±0.16 ±7.8 ±26 ±0.005 ±0.09 ±0.11 ±0.18 ±3 ±0.5
by glomerular capillary but not systemic hypertension. Further-
more, if hypertension is superimposed on the diabetic state,
then antihypertensive therapy may be critical to the preserva-
tion of renal function. Consistent with this hypothesis, Parving
et al [22] and Mogensen [231 have reported that lowering blood
pressure reduced the rate of decline in GFR and the level of
proteinuria in hypertensive diabetics with early nephropathy. In
both instances, the regimens employed included a -adrenergic
blocker. As propranolol has been reported to reduce renal
plasma flow in patients with essential hypertension, administra-
tion of drugs of this class may also cause reduction in intrarenal
pressure. This hypothesis has yet to be tested in micropuncture
studies of glomerular dynamics in rats treated with f3 blockers.
Finally, it should be clear that the state of afferent arteriolar
resistance may be as important as the choice of agent in
determining whether or not a particular form of antihyper-
tensive therapy will be effective in preventing hemodynamical-
ly—mediated glomerular injury. In the untreated DOC-SALT
rat, afferent arteriolar resistance is increased compared to
normotensive controls, and declines significantly in response to
vasodilator therapy. Ultimately, it is this fall in preglomerular
resistance which causes glomerular capillary hypertension and
injury in treated rats. In contrast, Neugarten et al [241 examined
the effects of the HHR combination on glomerular damage in
rats with a severe form of nephrotoxic serum nephritis (NSN)
characterized by the presence of systemic hypertension. In that
model, rats treated with HHR had less proteinuria and his-
tologic evidence of glomerular injury than untreated NSN
animals. Micropuncture studies revealed that this reduction in
injury was associated with a reduction in glomerular capillary
pressure in treated rats. Thus, if afferent arteriolar resistance is
already maximally reduced prior to therapy, then glomerular
capillary pressure will fall with reduction in mean arterial
pressure, regardless of the class of drug administered. Unfor-
tunately, as it is likely to be impossible to determine the state of
the preglomerular vessels in patients with renal disease, it may
be impossible to predict whether or not vasodilator therapy will
be associated with protection from or persistence of glomerular
injury in a particular patient. Therefore, antihypertensive
agents with the proven ability to reduce glomerular capillary
pressure in experimental renal disease may be the drugs of
choice for all patients with hypertension and renal disease.
In summary, rats made hypertensive by uninephrectomy and
six weeks of treatment with desoxycorticosterone and high salt
intake exhibited striking structural abnormalities of their
glomeruli and increased urinary protein excretion, both in
association with augmented glomerular transcapillary hydraulic
pressure—gradients. Normalization of systemic blood pressure
by administration of hydrochlorthiazide, hydralazine and reser-
pine failed to reduce glomerular capillary hydraulic pressure or
completely protect DOC-SALT rats from developing protein-
uria and morphologic evidence of glomerular injury. These
findings lend further support for the view that glomerular
capillary hypertension predisposes to glomerular injury in the
setting of systemic arterial hypertension and provide an attrac-
tive explanation for the observation that glomerular injury may
persist despite antihypertensive therapy in this experimental
model of hypertension.
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Glossary
mean femoral artery pressure, mm Hg
protein concentration, g/l00 ml
desoxycorticosterone acetate
glomerular filtration rate (whole kidney), mi/mm
blood hematocrit in femoral artery, vol/100 ml
hydrochlorthiazide, hydralazine and reserpine
glomerular capillary ultrafiltration coefficient, ni/s mm Hg
hydraulic pressure, mm Hg
— glomerular transcapillary hydraulicpressure difference, PGC
— PT, mm Hg
colloid osmotic pressure, mm Hg
glomerular transcapillary oncotic pressure difference, Tc —
ITT, mm Hg
arteriolar plasma flow, nI/mm
renal plasma flow (whole kidney), mI/mm
resistance to blood flow, dyne . s cm5 )< l0I
single nephron filtration fraction
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